Autotransplants for Hodgkin's disease in first relapse or second remission: A report from the autologous blood and marrow transplant registry (ABMTR)

Bone Marrow Transplantation

Volumn 27, Issue 4, 2001, Pages 387-396

  Lazarus, H M ^a   Loberiza, F R ^b   Zhang, M J ^b   Armitage, J O ^c   Ballen, K K ^d   Bashey, A ^e   Bolwell, B J ^f   Burns, L J ^g   Freytes, C O ^h   Gale, R P ⁱ   Gibson, J ^j   Herzig, R H ^k   LeMaistre, C F ^l   Marks, D ^m   Mason, J ⁿ   Miller, A M ^o   Milone, G A ^p   Pavlovsky, S ^p   Reece, D E ^q   Rizzo, J D ^b   Van Besien, K ^r   Vose, J M ^c   Horowitz, M M ^b   more..

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

ⁱ Center for Advanced Studies in Leukemia   (United States)

^j ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^k UNIVERSITY OF LOUISVILLE   (United States)

^l TEXAS TRANSPLANT INSTITUTE   (United States)

^m BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

ⁿ SCRIPPS RESEARCH INSTITUTE   (United States)

^o TULANE UNIVERSITY MEDICAL CENTER   (United States)

^p Fundaleu   (Argentina)

^q UNIVERSITY OF KENTUCKY   (United States)

^r UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

more..

Author keywords

Autotransplant; Hodgkin's disease; Relapse; Second complete remission

Indexed keywords

BLEOMYCIN; CARMUSTINE; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; LACTATE DEHYDROGENASE; MELPHALAN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW; CANCER RECURRENCE; CANCER REGRESSION; CHEMOTHERAPY; CHILD; CONTROLLED STUDY; DATA ANALYSIS; DEATH; DISEASE COURSE; DRUG MEGADOSE; DRUG RESISTANCE; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; REGISTER; STATISTICS; STEM CELL; SURVIVAL; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; CAUSE OF DEATH; CHILD; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECURRENCE; REGISTRIES; REMISSION INDUCTION; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 17744384690     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702796     Document Type: Article

References (60)

1. Cancer statistics 1998
2. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD
3. Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, Ch1VPP/EVA, in the initial treatment of Hodgkin's disease
4. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: A preliminary report
5. An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV hybrid program
6. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease
7. BEACOPP: A new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: Interim report from a trial of the German Hodgkin's lymphoma study group
8. Radiation therapy versus combination chemotherapy in the treatment of early stage Hodgkin's disease: Seven-year results of a prospective randomized trial
9. Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: Eight-year update of an Italian prospective randomized trial
10. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: A meta-analysis of 23 randomized trials involving 3,888 patients
11. Treatment of advanced stage massive mediastinal Hodgkin's disease: The case for combined modality treatment
12. A randomized study in Stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alternation of MOPP with ABVD: A European organization for research and treatment of cancer lymphoma cooperative Pierre-et-Marie-Curie controlled clinical trial
13. Treatment of advanced Hodgkin's disease with chemotherapy. Comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the national cancer institute of Canada clinical trials group
14. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: The 8-years results of the Intergroup trial
15. LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: Results of a British National Lymphoma investigation trial
16. Long-term results of MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin's disease
17. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure
18. Primary and salvage chemotherapy in advanced Hodgkin's disease: The Milan cancer institute experience
19. MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease
20. Phase II study of MOPLACE chemotherapy for patients with previously treated Hodgkin's disease: A CALGB study
21. Is there an effective salvage therapy for advanced Hodgkin's disease?
22. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD
23. Results of CAV (CCNU, melphalan, and VP-16) as third-line salvage therapy for Hodgkin's disease
24. Etoposide, vinblastine, and doxorubicin: An active regimen for the treatment of Hodgkin's disease in relapse following MOPP
25. Nonparametric estimation from incomplete observations
26. Regression models and life tables
27. Testing for center effects in multicenter survival studies: A Monte Carlo comparison of fixed and random effects
28. Dose intensification with autologous bone marrow transplantation in a relapsed and resistant Hodgkin's disease: Results of a BNLI randomized trial
29. Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients
30. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease
31. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients
32. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: Results from the EBMT
33. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed or refractory Hodgkin's disease: Results in 85 analysis of prognostic factors
34. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy
35. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: Analysis of 280 patients from the French registry
36. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: A prognostic model for treatment outcomes
37. Intensive therapy with cyclophosphamide, carmustine, etoposide ± cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy
38. Autologous stem cell transplantation (ASCT) for poor prognostic Hodgkin's disease (HD): Comparative results with two CBV regimens and importance of disease status at transplant
39. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: Value of pretransplant disease status for predicting outcome
40. High-dose therapy and autologous stem cell rescue for poor risk and refractory lymphoma: A single centre experience of 123 patients
41. Intensive chemotherapy with cyclophosphamide, carmustine and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease
42. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: Importance of disease status at transplant
43. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma
44. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease
45. High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease - A pragmatic prognostic index
46. Autologous stem cell transplantation for refractory and relapsed Hodgkin's disease: Factors predictive of prolonged survival
47. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices
48. High lactate dehydrogenase level is associated with an adverse outlook in autografting for Hodgkin's disease
49. High-dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: Long term follow-up in 128 patients
50. Allogeneicm syngeneic, and autologous marrow transplantation for Hodgkin's disease: The 21 year Seattle experience
51. Progressive disease after ABMT for Hodgkin's disease
52. Development of immunotoxins for potential clinical use in Hodgkin's disease
53. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin
54. A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma
55. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody
56. Phase I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: Complete response in a patient with Hodgkin's disease refractory to chemotherapy
57. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease
58. Single and double autotransplants for relapsing/refractory Hodgkin's disease: Results of two consecutive trials